Composition:
Each orodispersible tablet contains 90 mg ticagrelor 

Therapeutic indications: 
Lingabrique, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with:

- Acute coronary syndromes (ACS) or 

- A history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.